Kazia says Sovargen doses first patient in Phase 1b/2a paxalisib trial for rare seizure disorders, triggers $2 million payment

By Public Technologies
  • Sovargen dosed the first patient in a Phase 1b/2a trial of paxalisib for rare, treatment-resistant seizure disorders.
  • No clinical results have been presented; data are expected later as enrollment and study follow-up continue.
  • The start of dosing triggered a USD 2 million development milestone payment to Kazia under a 2024 licensing deal.
  • The agreement shifts epilepsy development and commercialization to Sovargen in most markets, creating potential milestones up to USD 17 million.
  • Kazia retains paxalisib’s main clinical focus in oncology while the partner tests the drug’s potential in neurological indications.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kazia Therapeutics Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609220730PR_NEWS_USPR_____NY51650) on September 22, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.